Are you Dr. Dreisbach?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 94 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
34490 Bob Hope Dr
Rancho Mirage, CA 92270Phone+1 760-568-3613Fax+1 760-340-5189
Summary
- Dr. Luke Dreisbach, MD is an oncologist in Rancho Mirage, California. He is currently licensed to practice medicine in California, Wisconsin, and Arizona. He is affiliated with Eisenhower Health.
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1998 - 2001- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1994 - 1997
McGovern Medical School at UTHealthClass of 1994
Certifications & Licensure
AZ State Medical License 1996 - Present
CA State Medical License 2000 - 2025
WI State Medical License 1997 - 1999- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:San Diego Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
- Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2009 Oct 19
- Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsAnother patient with candida vertebral osteomyelitis treated with liposomal amphotericin B.Lawrence A. Cone, Luke Dreisbach, Phillip Dreisbach, Moxelle Wuesthoff
Surgical Neurology. 2005-06-01 - 329 citationsPhase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett
Blood. 2008-01-01 - 74 citationsContinuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert
Nature Medicine. 2020-10-05
Professional Memberships
- Member
